Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK to Build Research Centers in Shanghai (China)

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline (GSK) says it will create a new research center in Shanghai, China this year backed by an initial $40 million investment, and it intends the center to grow into a worldwide powerhouse. GSK plans to recruit 50 to 100 top international scientists to the center, and in 10 years GSK plans to have the Shanghai center staffed with 1,000 research scientists. The center will focus on neurodegenerative disorders like Parkinson's, Alzheimer's, and multiple sclerosis. GSK chose Shanghai over a location in India or South Korea because Shanghai is a hub for foreign drug makers, because the city will be attractive to international research scientists, and because it has many prestigious universities and hospitals. The company is still looking for a specific location. In the last 12 months, both Novartis and Eli Lilly announced $100 million investments in creating research centers in China. (Click here for more

You may also be interested in...



China Expansion: R&D Staffs Growing Rapidly – Shanghai Forum

SHANGHAI - GlaxoSmithKline plans to double its R&D staff in China to roughly 350 by the end of 2009, GlaxoSmithKline China's R&D head of operation management and alliances Carol Zhu said during the ChinaBio Investor Forum 2008

Vous Has Advisors To Guide Growth In Promising Personalized Vitamin Space

Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.

Targeting Exciting Inflammasome Field, NodThera Raises $55m

UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.

UsernamePublicRestriction

Register

CO180755

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel